{ "version": "2.2", "instance": { "iva-20230630x6ka.htm iva-20230630xex99d1.htm": { "nsprefix": "iva", "nsuri": "http://www.inventivapharma.com/20230630", "dts": { "schema": { "local": [ "iva-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "calculationLink": { "local": [ "iva-20230630_cal.xml" ] }, "definitionLink": { "local": [ "iva-20230630_def.xml" ] }, "labelLink": { "local": [ "iva-20230630_lab.xml" ] }, "presentationLink": { "local": [ "iva-20230630_pre.xml" ] }, "inline": { "local": [ "iva-20230630x6ka.htm", "iva-20230630xex99d1.htm" ] } }, "keyStandard": 174, "keyCustom": 171, "axisStandard": 23, "axisCustom": 2, "memberStandard": 35, "memberCustom": 69, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2022": 7, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 1, "http://www.inventivapharma.com/20230630": 1 }, "contextCount": 305, "entityCount": 1, "segmentCount": 108, "elementCount": 565, "unitCount": 15, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 679, "http://xbrl.sec.gov/dei/2022": 9 }, "report": { "R1": { "role": "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630x6ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630x6ka.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition", "longName": "00100 - Statement - Unaudited interim condensed consolidated statement of financial position", "shortName": "Unaudited interim condensed consolidated statement of financial position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:NoncurrentAssets", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R3": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss", "longName": "00200 - Statement - Unaudited interim condensed consolidated statement of (income) loss", "shortName": "Unaudited interim condensed consolidated statement of (income) loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R4": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss", "longName": "00300 - Statement - Unaudited interim condensed consolidated statement of comprehensive (income) loss", "shortName": "Unaudited interim condensed consolidated statement of comprehensive (income) loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R5": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "longName": "00400 - Statement - Unaudited interim condensed consolidated statement of changes in shareholders' equity", "shortName": "Unaudited interim condensed consolidated statement of changes in shareholders' equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_r8grzwPuCUa-XqkeX0h5HQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_Rgxi5B2XCESSyhg2ICx_YQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R6": { "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "longName": "00500 - Statement - Unaudited interim condensed consolidated statement of cash flows", "shortName": "Unaudited interim condensed consolidated statement of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:AdjustmentsForDepreciationAmortisationAndProvisions", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R7": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformation", "longName": "10101 - Disclosure - Company information", "shortName": "Company information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance", "longName": "10201 - Disclosure - Basis of preparation and statement of compliance", "shortName": "Basis of preparation and statement of compliance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples", "longName": "10301 - Disclosure - Accounting Principles", "shortName": "Accounting Principles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheet", "longName": "10401 - Disclosure - Notes to the consolidated balance sheet", "shortName": "Notes to the consolidated balance sheet", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatement", "longName": "10501 - Disclosure - Notes to the income statement", "shortName": "Notes to the income statement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation", "longName": "10601 - Disclosure - Other financial information", "shortName": "Other financial information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:DisclosureOfOtherFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:DisclosureOfOtherFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies", "longName": "20302 - Disclosure - Accounting Principles (Policies)", "shortName": "Accounting Principles (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables", "longName": "30203 - Disclosure - Basis of preparation and statement of compliance (Tables)", "shortName": "Basis of preparation and statement of compliance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables", "longName": "30303 - Disclosure - Accounting Principles (Tables)", "shortName": "Accounting Principles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables", "longName": "30403 - Disclosure - Notes to the consolidated balance sheet (Tables)", "shortName": "Notes to the consolidated balance sheet (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables", "longName": "30503 - Disclosure - Notes to the income statement (Tables)", "shortName": "Notes to the income statement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables", "longName": "30630 - Disclosure - Other financial information (Tables)", "shortName": "Other financial information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "longName": "40101 - Disclosure - Company information - Amendments to Contract CRO with Pharmaceutical Research Associates B.V. & Service Agreement with Summit Clinical Research LLC (Details)", "shortName": "Company information - Amendments to Contract CRO with Pharmaceutical Research Associates B.V. & Service Agreement with Summit Clinical Research LLC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:NumberOfActiveClinicalSitesInNativ3Trial", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "iva:CompanyInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:NumberOfActiveClinicalSitesInNativ3Trial", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "iva:CompanyInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "longName": "40102 - Disclosure - Company information - CTTQ (Details)", "shortName": "Company information - CTTQ (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "Duration_5_22_2023_To_5_22_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_SH8bAzjrCUSGZbW174xFNQ", "name": "iva:AmountInvoicedToCounterparty", "unitRef": "Unit_Standard_USD__H0_gQ82LUqsmflH9dlbEw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_26_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_rEIXeWrYGE62HTs7cuvUNA", "name": "iva:CommitmentsAmountPayableForServicesReceivedUnderContractMaximumBonusOrMalusAmount", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R21": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "longName": "40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)", "shortName": "Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_49vZR1ewEkapmQC0QpH2zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_49vZR1ewEkapmQC0QpH2zw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "longName": "40202 - Disclosure - Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)", "shortName": "Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_USD_EUR__EGlo9Cdm0W-GqQZBSHBXw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_USD_EUR__EGlo9Cdm0W-GqQZBSHBXw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "longName": "40301 - Disclosure - Accounting Principles - Fair value measurement (Details)", "shortName": "Accounting Principles - Fair value measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_CFlL9Brt3EyHYBf4IItNZg", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R24": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "longName": "40302 - Disclosure - Accounting principles - Going concern (Details)", "shortName": "Accounting principles - Going concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfGoingConcernExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R25": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "longName": "40401 - Disclosure - Notes to the consolidated balance sheet - Intangible assets (Details)", "shortName": "Notes to the consolidated balance sheet - Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "As_Of_12_31_2022_tNUK3TI5jEafLnSesgJgBw", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_mpC3Sv7BmEODudBHcprrwA", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "iva:DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R26": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails", "longName": "40402 - Disclosure - Notes to the consolidated balance sheet - Property, Plant and Equipment (Details)", "shortName": "Notes to the consolidated balance sheet - Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_MJx74McLlk6lg2hIdEi65g", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R27": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "longName": "40403 - Disclosure - Notes to the consolidated balance sheet - Property, Plant and Equipment - Additional Information (Details)", "shortName": "Notes to the consolidated balance sheet - Property, Plant and Equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ChangesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ChangesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails", "longName": "40404 - Disclosure - Notes to the consolidated balance sheet - Other Non-Current Assets (Details)", "shortName": "Notes to the consolidated balance sheet - Other Non-Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "longName": "40405 - Disclosure - Notes to the consolidated balance sheet - Other Non-Current Assets - Additional Information (Details)", "shortName": "Notes to the consolidated balance sheet - Other Non-Current Assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:IncreaseDecreaseInLongTermDepositAccounts", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:IncreaseDecreaseInLongTermDepositAccounts", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDeferredTaxAssetDetails", "longName": "40406 - Disclosure - Notes to the consolidated balance sheet -Deferred tax asset (Details)", "shortName": "Notes to the consolidated balance sheet -Deferred tax asset (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "longName": "40407 - Disclosure - Notes to the consolidated balance sheet - Inventories (Details)", "shortName": "Notes to the consolidated balance sheet - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_2bWV4ppqBEe08xEoNUOtLg", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R32": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "longName": "40408 - Disclosure - Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Trade Receivables (Details)", "shortName": "Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_wrBvmtOUSkObA2Bwn59RpQ", "name": "iva:LicensingAndCollaborationAgreementAmountInvoicedToCounterpartyNetOfWithholdingTaxes", "unitRef": "Unit_Standard_USD__H0_gQ82LUqsmflH9dlbEw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R33": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "longName": "40409 - Disclosure - Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Other Current Assets and Receivables (Details)", "shortName": "Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Other Current Assets and Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:OtherCurrentTaxReceivables", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R34": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "longName": "40410 - Disclosure - Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Additional Information (Details)", "shortName": "Notes to the consolidated balance sheet - Trade Receivables and Other Current Assets and Receivables - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_dei_LegalEntityAxis_iva_InventivaIncMember_j_376jqcM0CqeQN6eQAxaQ", "name": "iva:CirAndOtherResearchTaxCreditsReceived", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R35": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "longName": "40411 - Disclosure - Notes to the consolidated balance sheet - Cash and Cash Equivalents (Details)", "shortName": "Notes to the consolidated balance sheet - Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:Cash", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R36": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "longName": "40412 - Disclosure - Notes to the consolidated balance sheet - Shareholders' equity - Share capital (Details)", "shortName": "Notes to the consolidated balance sheet - Shareholders' equity - Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_6_30_2022_cPalrHYu9kS7umhJvoDI9A", "name": "ifrs-full:IssueOfEquity", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_3iYx-RUDOU6GY8gDxxlJyQ", "name": "ifrs-full:NumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_LkvHVwsExkOi97xlUB9YLQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R37": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "longName": "40413 - Disclosure - Notes to the consolidated balance sheet Shareholders' Equity - Share warrants plans (Details)", "shortName": "Notes to the consolidated balance sheet Shareholders' Equity - Share warrants plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_bedCPv-_kEeRb8xVyUsLLw", "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "unitRef": "Unit_Divide_EUR_shares_buoz4O2CCUO-_nbB7nWptw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_bedCPv-_kEeRb8xVyUsLLw", "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "unitRef": "Unit_Divide_EUR_shares_buoz4O2CCUO-_nbB7nWptw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "longName": "40414 - Disclosure - Notes to the consolidated balance sheet Shareholders' Equity - Characteristics of BSA share warrant plans (Details)", "shortName": "Notes to the consolidated balance sheet Shareholders' Equity - Characteristics of BSA share warrant plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_GEjhWj9W6Ui22_WDdk89XA", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_buoz4O2CCUO-_nbB7nWptw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_5_25_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_GEjhWj9W6Ui22_WDdk89XA", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_buoz4O2CCUO-_nbB7nWptw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "longName": "40415 - Disclosure - Notes to the consolidated balance sheet Shareholders' Equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)", "shortName": "Notes to the consolidated balance sheet Shareholders' Equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_J8qs6xGrp0iEizh__94YWQ", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_J8qs6xGrp0iEizh__94YWQ", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "longName": "40416 - Disclosure - Notes to the consolidated balance sheet - Free share awards (Details)", "shortName": "Notes to the consolidated balance sheet - Free share awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "longName": "40417 - Disclosure - Notes to the consolidated balance sheet - Financial debt (Details)", "shortName": "Notes to the consolidated balance sheet - Financial debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails", "longName": "40418 - Disclosure - Notes to the consolidated balance sheet - Financial debt - Movements in the period break down (Details)", "shortName": "Notes to the consolidated balance sheet - Financial debt - Movements in the period break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_12_31_2022_tNUK3TI5jEafLnSesgJgBw", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:SubscriptionOfLeaseLiabilities", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R43": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "longName": "40419 - Disclosure - Notes to the consolidated balance sheet - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "shortName": "Notes to the consolidated balance sheet - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_6_30_2022_cPalrHYu9kS7umhJvoDI9A", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_6hx0acn06kaEkAQjE7swVA", "name": "iva:NumberOfLoanAgreements", "unitRef": "Unit_Standard_loan_tfEolgiSR0yxJijkdISqnQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R44": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "longName": "40420 - Disclosure - Notes to the consolidated balance sheet - Credit facility agreement with the European Investment Bank (Details)", "shortName": "Notes to the consolidated balance sheet - Credit facility agreement with the European Investment Bank (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_yRVpyu2bo0SCIjuSKAjpmQ", "name": "ifrs-full:NotionalAmount", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R45": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "longName": "40421 - Disclosure - Notes to the consolidated balance sheet - Derivatives (Details)", "shortName": "Notes to the consolidated balance sheet - Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_NNinyS4Uj0S0rJnOauQBsw", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_NNinyS4Uj0S0rJnOauQBsw", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "longName": "40422 - Disclosure - Notes to the consolidated balance sheet - Lease liabilities (Details)", "shortName": "Notes to the consolidated balance sheet - Lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_KyW82TiM7UyKkZbuXEVkkw", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R47": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails", "longName": "40423 - Disclosure - Notes to the consolidated balance sheet - Net provision (Details)", "shortName": "Notes to the consolidated balance sheet - Net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "longName": "40424 - Disclosure - Notes to the consolidated balance sheet - Change in net provision (Details)", "shortName": "Notes to the consolidated balance sheet - Change in net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_12_31_2022_tNUK3TI5jEafLnSesgJgBw", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R49": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails", "longName": "40425 - Disclosure - Notes to the consolidated balance sheet - Breakdown of expense recognized for the period (Details)", "shortName": "Notes to the consolidated balance sheet - Breakdown of expense recognized for the period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails", "longName": "40426 - Disclosure - Notes to the consolidated balance sheet - Trade payables and other current liabilities (Details)", "shortName": "Notes to the consolidated balance sheet - Trade payables and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:TradePayablesAndOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R51": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails", "longName": "40427 - Disclosure - Notes to the consolidated balance sheet - Trade payables (Details)", "shortName": "Notes to the consolidated balance sheet - Trade payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails", "longName": "40428 - Disclosure - Notes to the consolidated balance sheet - Other current liabilities (Details)", "shortName": "Notes to the consolidated balance sheet - Other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "longName": "40429 - Disclosure - Notes to the consolidated balance sheet - Financial assets and liabilities (Details)", "shortName": "Notes to the consolidated balance sheet - Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R54": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails", "longName": "40501 - Disclosure - Notes to the income statement - Revenues and other income (Details)", "shortName": "Notes to the income statement - Revenues and other income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "longName": "40502 - Disclosure - Notes to the income statement - Narratives (Details)", "shortName": "Notes to the income statement - Narratives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "iva:CurrentTaxCreditResearchCurrentYear", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_mlo4UGBk60GDsbTVJS2wWg", "name": "iva:OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R56": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "longName": "40503 - Disclosure - Notes to the income statement - Operating expenses (Details)", "shortName": "Notes to the income statement - Operating expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:Disposables", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:ResearchAndDevelopmentMarketingTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "iva:Disposables", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:ResearchAndDevelopmentMarketingTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails", "longName": "40504 - Disclosure - Notes to the income statement - Personnel costs and headcount (Details)", "shortName": "Notes to the income statement - Personnel costs and headcount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_ca4r0EMV3E-tVvoHrbUPWQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_ca4r0EMV3E-tVvoHrbUPWQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails", "longName": "40505 - Disclosure - Notes to the income statement - Other operating income and expenses - (Details)", "shortName": "Notes to the income statement - Other operating income and expenses - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_6_30_2022_cPalrHYu9kS7umhJvoDI9A", "name": "ifrs-full:MiscellaneousOtherOperatingIncome", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_6_30_2022_cPalrHYu9kS7umhJvoDI9A", "name": "ifrs-full:MiscellaneousOtherOperatingIncome", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails", "longName": "40506 - Disclosure - Notes to the income statement - Financial income and expenses (Details)", "shortName": "Notes to the income statement - Financial income and expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementIncomeTaxDetails", "longName": "40507 - Disclosure - Notes to the income statement - Income tax (Details)", "shortName": "Notes to the income statement - Income tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_jp-SHP75E0ar2oX_TqJO7A", "name": "ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_jp-SHP75E0ar2oX_TqJO7A", "name": "ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "longName": "40508 - Disclosure - Notes to the income statement - Basic and diluted loss per share (Details)", "shortName": "Notes to the income statement - Basic and diluted loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_6_30_2023_QEKwWe754keX2tnzysBtkg", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails", "longName": "40601 - Disclosure - Other financial information (Details)", "shortName": "Other financial information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2023_aq8TlLDWeEahbL41AUzYFA", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_nkdSnUR-60OzeBEUx_SQqg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationRelatedPartyTransactionsDetails", "longName": "40602 - Disclosure - Other financial information - Related-party transactions (Details)", "shortName": "Other financial information - Related-party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_wruZ6W_nMku_N7UVUbnHug", "name": "iva:PercentageOfSeverancePaymentSubjectToPerformanceCondition", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_wruZ6W_nMku_N7UVUbnHug", "name": "iva:PercentageOfSeverancePaymentSubjectToPerformanceCondition", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "longName": "40603 - Disclosure - Other financial information - Events after the reporting date (Details)", "shortName": "Other financial information - Events after the reporting date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "As_Of_6_30_2022_3iYx-RUDOU6GY8gDxxlJyQ", "name": "ifrs-full:ParValuePerShare", "unitRef": "Unit_Divide_EUR_shares_buoz4O2CCUO-_nbB7nWptw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_30_2023_To_8_30_2023_GzuNCsq0LkiM1P0KMrsBMQ", "name": "iva:SubscriptionPricePerShare", "unitRef": "Unit_Divide_EUR_shares_buoz4O2CCUO-_nbB7nWptw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } }, "R65": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails", "longName": "40604 - Disclosure - Other financial information - Licensing agreement with Hepalys (Details)", "shortName": "Other financial information - Licensing agreement with Hepalys (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_9_20_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_-S7Kg5hb1UySzSNEzqA7iQ", "name": "iva:LicenseAndCollaborationAgreementUpfrontFeeReceivable", "unitRef": "Unit_Standard_USD__H0_gQ82LUqsmflH9dlbEw", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_20_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_StatementGeographicalAxis_country_KR_jzfZ9ZeaFka30RKukajT-g", "name": "iva:PercentageOfPatientsWithSignificantFibrosis", "unitRef": "Unit_Standard_pure_8cWEIrf0skylAx1TbjlqlA", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20230630xex99d1.htm", "unique": true } } }, "tag": { "iva_SupportCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SupportCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to support costs.", "label": "Support costs", "negatedLabel": "Support costs (including taxes)" } } }, "auth_ref": [] }, "iva_OtherOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherOperatingExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other operating expenses.", "label": "Other operating expenses", "negatedLabel": "Other operating expenses" } } }, "auth_ref": [] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_ProductsAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProductsAndServicesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [member]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r144", "r185" ] }, "iva_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DirectorsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Directors.", "label": "Directors" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r111" ] }, "iva_ServiceProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ServiceProvidersMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to service providers.", "label": "Service Providers" } } }, "auth_ref": [] }, "iva_PayrollTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PayrollTaxes", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "A class of employee benefits expense that represents payroll taxes.", "label": "Payroll taxes", "negatedLabel": "Payroll taxes" } } }, "auth_ref": [] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r18", "r104", "r107", "r108", "r116", "r126", "r148", "r149", "r150", "r151", "r168", "r190" ] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods", "terseLabel": "Current taxes" } }, "en": { "role": { "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]" } } }, "auth_ref": [ "r218" ] }, "iva_TaxCreditsReceivableResearchCreditsFromCurrentTaxYearCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TaxCreditsReceivableResearchCreditsFromCurrentTaxYearCurrent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of research tax credit receivables attributable to the current tax year, classified as current.", "label": "Tax Credits Receivable, Research Credits from Current Tax Year, Current", "terseLabel": "Research tax credits receivable from current tax year" } } }, "auth_ref": [] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r100", "r110", "r150", "r183", "r184", "r237" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Premiums related to share capital" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Foreign currency forwards contract", "verboseLabel": "Licensing agreement with Hepalys" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange gains / (losses)" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r73", "r74" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r39", "r40", "r61", "r62", "r65", "r66", "r67", "r68", "r69", "r114", "r120", "r121", "r240", "r242" ] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial liabilities", "terseLabel": "Long-term debt - derivatives", "verboseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r213" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r53", "r55", "r95" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Currency translation differences" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r21", "r32" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "terseLabel": "Exercise price per share" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r236" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited/ Lapsed" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r236" ] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r144", "r185" ] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of comprehensive (income) loss" } } }, "auth_ref": [] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r18", "r104", "r107", "r108", "r116", "r148", "r149", "r150", "r151", "r168", "r190", "r196" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "totalLabel": "Total other operating income" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r212" ] }, "iva_Bsa2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa2018PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018 plan.", "label": "BSA - 2018 plan" } } }, "auth_ref": [] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Sharebased compensation expense" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r111" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r1", "r28", "r79", "r81", "r90", "r182" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r50" ] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r4" ] }, "ifrs-full_OtherBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherBorrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other borrowings", "terseLabel": "Other loans", "verboseLabel": "Other loans and similar borrowings" } }, "en": { "role": { "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Capital increase", "verboseLabel": "Proceeds from issuance of shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r175" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of debt" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r237" ] }, "iva_PersonnelCostsAndHeadcount": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PersonnelCostsAndHeadcount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "Personnel costs and headcount", "label": "Personnel costs and headcount", "terseLabel": "Schedule of personnel costs and headcount" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r237" ] }, "iva_NonCurrentLongTermDepositsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NonCurrentLongTermDepositsFromCustomers", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents information about non current long term deposits from customers.", "label": "Non Current Long Term Deposits From Customers", "terseLabel": "Longterm deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r100", "r110", "r150", "r183", "r184", "r237" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]", "terseLabel": "Net income (loss) for the period" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r211" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total debt", "verboseLabel": "Total debt" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, at fair value", "verboseLabel": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r117" ] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense, defined benefit plans", "negatedLabel": "Interest cost for the period" } }, "en": { "role": { "documentation": "The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]" } } }, "auth_ref": [ "r222" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r118", "r122", "r129" ] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows used in operations before tax, interest and changes in working capital", "totalLabel": "Cash flows used in operations before tax, interest and changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r180", "r234" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "OwnershipDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price (in euros)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r236" ] }, "iva_SharesIssuedPricePerShare1": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SharesIssuedPricePerShare1", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share price of equity shares issued.", "label": "Shares Issued Price Per Share 1", "terseLabel": "Issue price" } } }, "auth_ref": [] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Between 3 and 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than five years." } } }, "auth_ref": [ "r190", "r194", "r198" ] }, "iva_AdjustmentsForDepreciationAmortisationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AdjustmentsForDepreciationAmortisationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Depreciation, Amortisation and Provisions", "terseLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "ifrs-full_LoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LoansReceived", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Loans received", "terseLabel": "Bank borrowings" } }, "en": { "role": { "documentation": "The amount of loans received." } } }, "auth_ref": [ "r212" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "OwnershipAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense, defined benefit plans", "negatedTotalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]" } } }, "auth_ref": [ "r222", "r224" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Less than 1 year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r17", "r107", "r108", "r151", "r190", "r198" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]", "terseLabel": "Non-adjusting events after reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r34" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r117" ] }, "iva_SalesTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SalesTaxReceivableCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of sales tax receivables, classified as current.", "label": "Sales Tax Receivable, Current", "terseLabel": "Sales tax receivable" } } }, "auth_ref": [] }, "ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax rate effect of adjustments for current tax of prior periods", "terseLabel": "Projected tax rate" } }, "en": { "role": { "documentation": "Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]" } } }, "auth_ref": [ "r219" ] }, "iva_EmployeeRelatedPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EmployeeRelatedPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to employee related payables.", "label": "Employee related payables", "verboseLabel": "Employee-related payables" } } }, "auth_ref": [] }, "iva_DepreciationAmortizationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DepreciationAmortizationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to depreciation, amortization and provisions.", "label": "Depreciation, amortization and provisions", "negatedLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "terseLabel": "Number of shares outstanding" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r25" ] }, "iva_EnergyAndLiquids": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EnergyAndLiquids", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to energy and liquids.", "label": "Energy and liquids", "negatedLabel": "Energy and liquids" } } }, "auth_ref": [] }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EntitysTotalForSubsidiariesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r53", "r55", "r95" ] }, "ifrs-full_FinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r127", "r128", "r147", "r153" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "verboseLabel": "Intangible Assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "iva_Disposables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Disposables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to disposables.", "label": "Disposables", "negatedLabel": "Disposables" } } }, "auth_ref": [] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r111" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss, category [member]", "terseLabel": "Financial liabilities carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r131" ] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "More than 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r107", "r108", "r151", "r190", "r195", "r198" ] }, "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current accrued income including current contract assets", "terseLabel": "Current accrued income" } }, "en": { "role": { "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r213", "r216" ] }, "iva_ItSystems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ItSystems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to it systems.", "label": "IT Systems", "negatedLabel": "IT systems" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r70", "r77" ] }, "iva_Studies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Studies", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to studies.", "label": "Studies", "negatedLabel": "Studies" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r76" ] }, "iva_Patents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Patents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to patents.", "label": "Patents", "negatedLabel": "Patents" } } }, "auth_ref": [] }, "iva_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Fees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fees.", "label": "Fees", "negatedLabel": "Fees" } } }, "auth_ref": [] }, "ifrs-full_OtherContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherContingentLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other contingent liabilities [member]", "terseLabel": "Other" } }, "en": { "role": { "documentation": "This member stands for contingent liabilities that the entity does not separately disclose in the same statement or note. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r172" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r236" ] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share issue related cost", "negatedTerseLabel": "Transaction costs" } }, "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } } }, "auth_ref": [ "r210" ] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain", "terseLabel": "Foreign exchange gains" } }, "en": { "role": { "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r7", "r47" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r130" ] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_OtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherProvisionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions [member]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r59" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "verboseLabel": "Increase / (decrease) in operating and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r234" ] }, "ifrs-full_NoncurrentAccruedIncomeIncludingNoncurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentAccruedIncomeIncludingNoncurrentContractAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Non-current accrued income including non-current contract assets", "terseLabel": "Accrued income" } }, "en": { "role": { "documentation": "The amount of non-current accrued income including non-current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r213", "r216" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Noncurrent assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of movements in BSPCE and BSA share warrants and Bonus shares" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r236" ] }, "iva_NewBonusShareAwardPlanAga2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlanAga2021Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021)", "label": "AGA 2021 [Member]" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Long-term debt" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r213" ] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "Sales tax payables" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r216" ] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in intangible assets other than goodwill" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash used in investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r70", "r77" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Elimination of non-cash or non-operating income and expenses" } } }, "auth_ref": [] }, "iva_ProvisionForRetirementBenefitObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProvisionForRetirementBenefitObligations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of provision for retirement obligations during the period.", "label": "Provision For Retirement Benefit Obligations", "negatedLabel": "Provisions for retirement benefit obligations" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r19", "r86", "r182" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Guarantee Details", "verboseLabel": "Financial debt" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [line items]", "terseLabel": "Other operating income and expenses" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r15", "r97", "r98", "r99", "r139", "r142" ] }, "iva_FibroscanMachinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FibroscanMachinesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for fibroscan machines.", "label": "Fibroscan machines" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Total financial expenses" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r30" ] }, "ifrs-full_ChangesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ChangesInPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in property, plant and equipment", "terseLabel": "Increase in net value of property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r40" ] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } } }, "auth_ref": [ "r208" ] }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InterestIncomeOnCashAndCashEquivalents", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on cash and cash equivalents", "terseLabel": "Income from cash equivalents" } }, "en": { "role": { "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r12" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "terseLabel": "Items not recycled to income" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r166", "r167" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r56", "r57" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Schedule of trade payables break down by payment" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r208" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Issued", "verboseLabel": "Number of BSA issued" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r112", "r236" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r14", "r82", "r83" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Translation reserve" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r48" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows used in investing activities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Tax, interest and changes in operating working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r234" ] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r41", "r170", "r187" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of (income) loss" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r237" ] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks.", "label": "Loan Agreements With Syndicate of French Banks [Member]", "verboseLabel": "Loan agreements with a syndicate of French banks" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipments", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } } }, "auth_ref": [ "r8", "r40" ] }, "iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of minimum upfront payments for out-licensing, partnership or royalty transaction.", "label": "Minimum Upfront Payments For Out-Licensing, Partnership Or Royalty Transaction", "verboseLabel": "Minimum upfront payments for out-licensing, partnership or royalty transaction" } } }, "auth_ref": [] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r162", "r164" ] }, "ifrs-full_ShorttermContractsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShorttermContractsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term contract liabilities" } }, "en": { "role": { "documentation": "This member stands for short-term contracts with customers." } } }, "auth_ref": [ "r186" ] }, "iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinanceContractWithEuropeanInvestmentBankSecondTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to second tranche of the finance contract with European investment bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, Second Tranche [Member]", "terseLabel": "Finance contract with EIB, second tranche" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClassOfWarrantOrRightMaturityTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term of the warrants issued by the entity.", "label": "Class Of Warrant Or Right, Maturity Term", "terseLabel": "Maturity term of warrants" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Schedule of subsidiaries" } }, "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r85" ] }, "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [text block]", "terseLabel": "Schedule of commitments given and received" } }, "en": { "role": { "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]" } } }, "auth_ref": [ "r60" ] }, "iva_OptionToAcquireSharesInCompanyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OptionToAcquireSharesInCompanyPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Option to acquire shares in company, percentage", "label": "Option to acquire shares in company, percentage" } } }, "auth_ref": [] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r50" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "Cost of net debt" } }, "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } } }, "auth_ref": [ "r234" ] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Long-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r101" ] }, "iva_ExercisePeriodForShareAcquisitionOptionFromEffectiveDateOfLicensingAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExercisePeriodForShareAcquisitionOptionFromEffectiveDateOfLicensingAgreement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise period for share acquisition option from effective date of licensing agreement", "label": "Exercise period for share acquisition option from effective date of licensing agreement" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsWithSignificantFibrosis": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfPatientsWithSignificantFibrosis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of patients with significant fibrosis", "label": "Percentage of patients with significant fibrosis" } } }, "auth_ref": [] }, "iva_NumberOfEqualTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfEqualTranches", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information of number of equal tranches .", "label": "Number of Equal Tranches", "terseLabel": "Number of equal tranches" } } }, "auth_ref": [] }, "iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MaximumPotentialGrossProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of gross proceeds that the company will receive from exercise of warrants.", "label": "Maximum Potential Gross Proceeds From Exercise Of Warrants", "terseLabel": "Maximum potential gross proceeds from exercise of warrants" } } }, "auth_ref": [] }, "iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of Company's share capital outstanding, issued as warrants by the entity.", "label": "Percentage Of Company's Share Capital Outstanding, Issued As Warrants", "terseLabel": "Percentage of Company's share capital outstanding, issued as warrants" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities carried at amortized cost", "verboseLabel": "Liabilities carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r133", "r158" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r132" ] }, "iva_PercentageOfDiscountToVolumeWeightedAverageTradingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfDiscountToVolumeWeightedAverageTradingPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to volume weighted average trading price of shares applied to the price of the stock offering.", "label": "Percentage Of Discount To Volume Weighted Average Trading Price", "verboseLabel": "Percentage of discount to volume weighted average trading price" } } }, "auth_ref": [] }, "iva_PercentageOfPopulationSufferingFromNash": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfPopulationSufferingFromNash", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of population suffering from NASH", "label": "Percentage of population suffering from NASH" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r119", "r123", "r188", "r212" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Between 1 and 3 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } } }, "auth_ref": [ "r190", "r193", "r198" ] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Actuarial gains or losses recognized in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r44" ] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through appropriation of retained earnings, equity", "terseLabel": "Appropriation of 2022 net income (loss)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r210" ] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r100", "r110", "r150", "r183", "r184", "r237" ] }, "iva_CommitmentAmountsPayablesForServicesReceivedUnderContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentAmountsPayablesForServicesReceivedUnderContracts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of bonus or malus payable on amount committed by the company to pay for services received under contract.", "label": "Commitment Amounts Payables for Services Received Under Contracts", "terseLabel": "Commitments amount payable for services received under contracts" } } }, "auth_ref": [] }, "iva_NumberOfBiopsiesUnderClinicalTrials": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfBiopsiesUnderClinicalTrials", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the number of clinical trial.", "label": "Number Of Biopsies Under Clinical Trials", "terseLabel": "Number of Biopsies Under the Phase III trial" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga2021BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlanAga2021BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-bis).", "label": "AGA 2021-bis" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlanAga20211Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-1)", "label": "AGA 2021-1" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementShortTermPotentialMilestonePaymentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicenseAndCollaborationAgreementShortTermPotentialMilestonePaymentReceivables", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of short-term potential milestone payment receivable by the entity under the license and collaboration agreement.", "label": "License And Collaboration Agreement, Short-Term Potential Milestone Payment Receivables", "verboseLabel": "Short-term potential milestone payment receivable" } } }, "auth_ref": [] }, "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement.", "label": "Aggregate Amount To Be Received Either In Exchange For New Shares Of The Company Or Through The Receipt Of Upfront Or Milestone Payments", "verboseLabel": "Aggregate amount to be received under the conditions precedent to the EIB Financing" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r63" ] }, "iva_NumberOfSiteRandomized": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSiteRandomized", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the number of sites randomized", "label": "Number of Site Randomized", "terseLabel": "Number of site randomized" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Tax credit received" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r75", "r174" ] }, "iva_ContractCroWithResearchAssociatesGroupeB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ContractCroWithResearchAssociatesGroupeB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails": { "parentTag": "ifrs-full_LiabilityAssetOfDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit obligation, at present value", "verboseLabel": "Retirement benefit obligations" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r225" ] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContract", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitment amount payable for services received under contract.", "label": "Commitments Amount Payable For Services Received Under Contract", "verboseLabel": "Amount committed to pay" } } }, "auth_ref": [] }, "iva_CurrentTaxCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The amount of current tax credit receivables", "label": "Current tax credit receivables", "terseLabel": "Tax receivables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r118", "r122", "r129" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-term deposits", "terseLabel": "Long-term deposit" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue" } }, "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } } }, "auth_ref": [ "r102", "r103" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Exchange rate at period end", "verboseLabel": "Exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, other equity instruments granted", "verboseLabel": "Fair value per AGA at grant date" } }, "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r112" ] }, "iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount related to reinvoicing of specific costs incurred on services with customer research organization accrued liabilities included in other income.", "label": "Other Income, Reinvoicing Of Specific Costs Under Service Agreement", "terseLabel": "Reinvoicing of specific costs related to CRO accrued liabilities included in other income" } } }, "auth_ref": [] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost, defined benefit plans", "negatedLabel": "Service cost for the period" } }, "en": { "role": { "documentation": "The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]" } } }, "auth_ref": [ "r222" ] }, "iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount related to reinvoicing of share of costs incurred under the licensing and collaboration agreements included in other income.", "label": "Other Income, Relating To Reinvoicing Of Share Of Costs Under Licensing And Collaboration Agreement", "terseLabel": "Reinvoicing of share of costs incurred included in other income" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease / (increase) in inventories" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r232" ] }, "iva_IfrsDebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsDebtInstrumentTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Ifrs Debt Instrument, Term", "verboseLabel": "Maturity term after the disbursement of the tranche" } } }, "auth_ref": [] }, "ifrs-full_NotLaterThanThreeMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NotLaterThanThreeMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "3 months or less" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } } }, "auth_ref": [ "r201", "r203", "r212" ] }, "iva_OtherIncomeFromOrdinaryActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherIncomeFromOrdinaryActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other income from ordinary activities.", "label": "Other income from ordinary activities", "terseLabel": "Other income", "totalLabel": "Other operating income" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]", "terseLabel": "General principles and statement of compliance" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares", "label": "Retained earnings excluding profit (loss) for the reporting period and treasury shares", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "iva_PercentageOfSeverancePaymentSubjectToPerformanceCondition": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfSeverancePaymentSubjectToPerformanceCondition", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to percentage of severance payment subject to performance condition.", "label": "Percentage Of Severance Payment Subject To Performance Condition", "terseLabel": "Percentage of severance payment subject to performance condition" } } }, "auth_ref": [] }, "iva_SeverancePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SeverancePayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of severance payment accrued.", "label": "Severance Payment", "terseLabel": "Severance payment" } } }, "auth_ref": [] }, "iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.", "label": "Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "iva_InventivaS.aMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "InventivaS.aMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva S.A, U.S. affiliate.", "label": "Inventiva S.A [Member]" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r9", "r62" ] }, "iva_CirAndOtherResearchTaxCreditsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CirAndOtherResearchTaxCreditsReceived", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of CIR and other research tax credits received during the period.", "label": "CIR and Other Research Tax Credits Received", "terseLabel": "CIR and other research tax credits received" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value measurement" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r238", "r239" ] }, "iva_PeriodToBecomeEligibleForFreeAllotmentOfShares": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PeriodToBecomeEligibleForFreeAllotmentOfShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period to become eligible for free allotment of shares .", "label": "Period To Become Eligible For Free Allotment Of Shares", "terseLabel": "Period to become eligible for free allotment of shares" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ForeignExchangeRatesAbstract", "lang": { "en-us": { "role": { "label": "Exchange rate (USD per EUR)" } } }, "auth_ref": [] }, "iva_NonCurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NonCurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount represents the non current advances of suppliers.", "label": "Non Current Advances To Suppliers", "terseLabel": "Advance payments - non-current", "verboseLabel": "Non-current advances to suppliers" } } }, "auth_ref": [] }, "iva_SubscriptionOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubscriptionOfLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of subscription of lease liabilities.", "label": "Subscription Of Lease Liabilities", "terseLabel": "Subscription of lease liabilities" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinanceContractWithEuropeanInvestmentBankFirstTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to first tranche of the finance contract with European Investment Bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, First Tranche [Member]", "terseLabel": "Finance contract with EIB, first tranche" } } }, "auth_ref": [] }, "iva_ExpirationNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExpirationNoticePeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The expiration of the term with a notice period.", "label": "Expiration Notice Period", "terseLabel": "Expiration term of notice period" } } }, "auth_ref": [] }, "iva_IfrsResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development expense member.", "label": "Ifrs Research And Development Expense [Member]", "terseLabel": "Research and development costs" } } }, "auth_ref": [] }, "iva_AccruedPayrollAndOtherEmployeeRelatedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccruedPayrollAndOtherEmployeeRelatedTaxes", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.", "label": "Accrued payroll and other employeerelated taxes", "terseLabel": "Accrued payroll and other employee-related taxes" } } }, "auth_ref": [] }, "iva_LongTermIncentivePlanInPerformanceUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermIncentivePlanInPerformanceUnitsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term incentive plan in performance units or \"PAGUP\".", "label": "Long-Term Incentive Plan In Performance Units [Member]", "terseLabel": "PAGUP" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Short-term deposits", "verboseLabel": "Other cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r235" ] }, "iva_WarrantAgreementWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantAgreementWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Warrant agreement with the European Investment Bank.", "label": "Warrant Agreement With The European Investment Bank [Member]", "terseLabel": "Warrant agreement with the European Investment Bank" } } }, "auth_ref": [] }, "iva_IfrsSalesAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsSalesAndMarketingExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for sales and marketing expense member.", "label": "Marketing - Business development expenses" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current asset", "terseLabel": "Other non-current assets", "totalLabel": "Other noncurrent assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r213" ] }, "iva_IfrsGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsGeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for general and administrative expense member.", "label": "General and administrative expenses" } } }, "auth_ref": [] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross", "terseLabel": "Laboratory inventories" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r39", "r61", "r66", "r69", "r114", "r121", "r124", "r188", "r240", "r242" ] }, "iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.", "label": "Proceeds From Sales Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "terseLabel": "Disposals of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccrualsClassifiedAsCurrentRelatingToScientificProjects", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accruals classified as current relating to scientific projects", "label": "Accruals classified as current relating to scientific projects", "terseLabel": "Accrued liabilities relating to scientific projects" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventories write-down" } }, "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } } }, "auth_ref": [ "r114", "r120", "r188", "r202", "r206", "r221", "r228", "r229", "r230" ] }, "iva_ClassOfWarrantOrRightMeasurementPeriodForSharePriceToDetermineNumberOfInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClassOfWarrantOrRightMeasurementPeriodForSharePriceToDetermineNumberOfInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Measurement period for share price to determine number of instruments granted", "label": "Class Of Warrant Or Right, Measurement period for share price to determine number of instruments granted", "terseLabel": "Measurement period for share price to determine number of instruments granted" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Weighted average share price", "verboseLabel": "Stock price at grant date (in euros)" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r109" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost, class [member]", "terseLabel": "Financial liabilities at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r135" ] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of changes in shareholders' equity" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradePayableAndOtherCurrentLiabilitiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Table]" } } }, "auth_ref": [] }, "iva_NumberOfCountriesInStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfCountriesInStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of countries involved in study", "label": "Number of countries in study" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradePayableAndOtherCurrentLiabilitiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Line Items]" } } }, "auth_ref": [] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContractMaximumBonusOrMalusAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContractMaximumBonusOrMalusAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of bonus or malus payable on amount committed by the company to pay for services received under contract.", "label": "Commitments, Amount Payable For Services Received Under Contract, Maximum Bonus Or Malus Amount", "terseLabel": "Bonus or malus maximum amount" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" ], "lang": { "en-us": { "role": { "label": "Statement of IFRS compliance [text block]", "terseLabel": "Basis of preparation and statement of compliance" } }, "en": { "role": { "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs." } } }, "auth_ref": [ "r6" ] }, "iva_LanifibranorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LanifibranorMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Lanifbranor", "label": "Lanifibranor [Member]", "terseLabel": "Lanifibranor" } } }, "auth_ref": [] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Total revenue and other income" } }, "en": { "role": { "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]" } } }, "auth_ref": [ "r217" ] }, "iva_LicensingAndCollaborationAgreementWithCttqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAndCollaborationAgreementWithCttqMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Licensing and collaboration agreement with CTTQ.", "label": "Licensing and collaboration agreement with CTTQ [Member]", "terseLabel": "Licensing and collaboration agreement with CTTQ" } } }, "auth_ref": [] }, "iva_NumberOfSitesInStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSitesInStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of sites involved in study", "label": "Number of sites in study" } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "negatedTerseLabel": "Personnel costs", "negatedTotalLabel": "Total personnel costs" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r0", "r33", "r159" ] }, "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current receivables from taxes other than income tax", "totalLabel": "Tax receivables" } }, "en": { "role": { "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]" } } }, "auth_ref": [ "r214" ] }, "iva_LicensingAndCollaborationAgreementAmountReceivedAttributableToWithholdingTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAndCollaborationAgreementAmountReceivedAttributableToWithholdingTaxes", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received by the entity from licensing and collaborative arrangements, attributable to withholding taxes.", "label": "Licensing And Collaboration Agreement, Amount Received Attributable To Withholding Taxes", "terseLabel": "Amount received attributable to withholding taxes" } } }, "auth_ref": [] }, "ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProvisionForTaxesOtherThanIncomeTaxMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Tax disputes" } }, "en": { "role": { "documentation": "This member stands for a provision for taxes other than income tax. Income taxes include all domestic and foreign taxes which are based on taxable profits. Income taxes also include taxes, such as withholding taxes, which are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity. [Refer: Other provisions [member]]" } } }, "auth_ref": [ "r227" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of exercisable shares" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r236" ] }, "iva_ThresholdSalesValueForCalculationOfRoyaltyPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ThresholdSalesValueForCalculationOfRoyaltyPayments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold sales value for calculation of royalty payments", "label": "Threshold sales value for calculation of royalty payments" } } }, "auth_ref": [] }, "iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ContractCroWithPharmaceuticalResearchAssociatesB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO With Pharmaceutical Research Associates B.V [Member]", "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "iva_TransactionsCostsIncurredFromWarrantsExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TransactionsCostsIncurredFromWarrantsExercises", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of transactions costs incurred from warrants exercises.", "label": "Transactions Costs Incurred From Warrants Exercises", "terseLabel": "Transactions costs" } } }, "auth_ref": [] }, "iva_WarrantsThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsThresholdTradingDays", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Warrants, Threshold Trading Days", "terseLabel": "Threshold trading days of warrants" } } }, "auth_ref": [] }, "iva_WarrantsStockPrice": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsStockPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock price used to calculate fair value of warrants.", "label": "Warrants, Stock Price", "terseLabel": "Stock price (\u20ac)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other financial information [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "iva_AmountReachedUnderConditionsPrecedentToFinancingArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountReachedUnderConditionsPrecedentToFinancingArrangement", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount reached by the entity under the conditions precedent to the Financing arrangement.", "label": "Amount Reached Under The Conditions Precedent To Financing Arrangement", "terseLabel": "Amount reached under the conditions precedent to the EIB Financing" } } }, "auth_ref": [] }, "iva_WarrantsCapOfPutOption": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsCapOfPutOption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cap of the put option used to calculate fair value of warrants.", "label": "Warrants, Cap of Put Option", "terseLabel": "Cap of the put option (m\u20ac)" } } }, "auth_ref": [] }, "iva_OtherFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherFinancialInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other financial information" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "iva_ClinicalTrialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClinicalTrialsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Clinical Trials(CRO).", "label": "Clinical Trials [Member]", "terseLabel": "CRO" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "verboseLabel": "Items recycled to income" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r166", "r167" ] }, "iva_MaximumPotentialAmountToBeRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MaximumPotentialAmountToBeRaised", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount to be raised under the sale of stock transaction.", "label": "Maximum Potential Amount To Be Raised", "terseLabel": "Maximum potential amount to be raised" } } }, "auth_ref": [] }, "iva_IfrsLicenseAndCollaborationAgreementUpfrontFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsLicenseAndCollaborationAgreementUpfrontFeeReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Upfront fee receivable.", "label": "IFRS License and Collaboration Agreement Upfront Fee Receivable", "terseLabel": "Upfront payment to be received" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r165" ] }, "iva_RoyaltyCertificateIssuanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RoyaltyCertificateIssuanceAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Royalty certificate issuance.", "label": "Royalty Certificate Issuance Amount", "terseLabel": "Royalty certificate issuance amount" } } }, "auth_ref": [] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r106" ] }, "iva_EstimatedAmountPayableUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EstimatedAmountPayableUnderAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the estimated amount payable under the agreement.", "label": "Estimated Amount Payable Under Agreement", "terseLabel": "Estimated amount payable" } } }, "auth_ref": [] }, "iva_ProceedsFromFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProceedsFromFinancing", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash proceeds from financing.", "label": "Proceeds From Financing", "terseLabel": "Gross cash proceeds" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "iva_NumberOfDaysWrittenNoticeForAccessibilityOfLongTermDeposit": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfDaysWrittenNoticeForAccessibilityOfLongTermDeposit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days written notice for long-term deposit to become accessible.", "label": "Number of days written notice for accessibility of long-term deposit", "terseLabel": "Number of days written notice for accessibility of long-term deposit" } } }, "auth_ref": [] }, "iva_LongTermDepositsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermDepositsTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of the long-term deposits of the entity.", "label": "Long-Term Deposits Term", "terseLabel": "Period of long-term deposit" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of basic and diluted loss per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r56" ] }, "iva_WarrantsUnitFairValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsUnitFairValue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Unit fair value used to calculate fair value of warrants.", "label": "Warrants, Unit Fair Value", "terseLabel": "Unit fair value (\u20ac)" } } }, "auth_ref": [] }, "iva_AdvancePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AdvancePaymentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for advance payment.", "label": "Advance payment" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r213" ] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current provisions for employee benefits", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r22" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "iva_BorrowingsEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BorrowingsEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate on borrowings.", "label": "Borrowings, effective interest rate" } } }, "auth_ref": [] }, "iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH.", "label": "Indication Of Continuation Of Recruitment For Phase Iii Trial Nativ3 Of Lanifibranor In Non-Cirrhotic NashASH [Member]", "terseLabel": "Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH" } } }, "auth_ref": [] }, "iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation approach for BSA share-based payment arrangement", "label": "Disclosure of valuation approach for BSA share-based payment arrangement [table text block]", "terseLabel": "Schedule of valuation approach for BSA arrangement" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLongTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInLongTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in long-term deposit accounts", "label": "Increase (decrease) in long-term deposit accounts", "terseLabel": "Increase in long-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r31", "r35", "r36", "r37", "r51", "r94", "r138" ] }, "iva_NumberOfActiveClinicalSitesInNativ3Trial": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfActiveClinicalSitesInNativ3Trial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of active clinical sites in NATiV3 trial", "label": "Number of active clinical sites in NATiV3 trial" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r100", "r110", "r150", "r183", "r184", "r237" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentDescription", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "iva_NumberOfSubjectsRandomized": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSubjectsRandomized", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of subjects randomized.", "label": "Number of Subjects Randomized", "terseLabel": "Number of subjects randomized" } } }, "auth_ref": [] }, "iva_LicensingAgreementWithHepalysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAgreementWithHepalysMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Licensing agreement with Hepalys.", "label": "Licensing Agreement With Hepalys [Member]", "terseLabel": "Licensing agreement with Hepalys" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange loss", "negatedLabel": "Foreign exchange losses" } }, "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r7", "r47" ] }, "iva_Bsa2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the BSA 2022 share-based payment plan", "label": "BSA 2022 [Member]", "terseLabel": "BSA 2022" } } }, "auth_ref": [] }, "iva_ReceiptOfPaymentsUnderLicensingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ReceiptOfPaymentsUnderLicensingArrangementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for receipt of payments under Licensing arrangements.", "label": "Receipt Of Payments Under Licensing Arrangements [Member]", "terseLabel": "Receipt of payments under Licensing arrangements" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease / (increase) in operating and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r234" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "iva_HepalysPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "HepalysPharmaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Hepalys Pharma, Inc.", "label": "Hepalys Pharma, Inc [Member]", "terseLabel": "Hepalys Pharma, Inc" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Other" } }, "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r233" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInTradeAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInTradeAccountsPayable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in trade accounts payable", "label": "Increase (decrease) in trade accounts payable", "terseLabel": "Increase in trade accounts payable" } } }, "auth_ref": [] }, "iva_LeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LeaseTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease term", "label": "Lease term" } } }, "auth_ref": [] }, "iva_Bsa20231ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa20231ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-1 share warrants plan.", "label": "BSA 2023-1 Share Warrant Plan [Member]", "terseLabel": "BSA 2023 plan", "verboseLabel": "BSA 2023-1 share warrants plan" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Schedule of other current assets and receivables" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r208" ] }, "iva_ReversalOfOtherProvisionsIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ReversalOfOtherProvisionsIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Reversal of other provisions, income", "label": "Reversal of other provisions, income", "terseLabel": "Reversal of provision" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDeferredTaxAssetDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred tax asset" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r13", "r16", "r38" ] }, "iva_LongTermIncentivePlanInPerformanceUnits2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermIncentivePlanInPerformanceUnits2023Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for 2023 long-term incentive plan in performance units or \"PAGUP 2023\".", "label": "Long-Term Incentive Plan In Performance Units, 2023 [Member]", "terseLabel": "PAGUP 2023" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } } }, "auth_ref": [ "r117", "r120", "r121", "r124", "r188" ] }, "iva_NewBonusShareAwardPlan20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBonusShareAwardPlan20231Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-1).", "label": "New Bonus Share Award Plan 2023-1 [Member]", "terseLabel": "AGA Plan 2023-1" } } }, "auth_ref": [] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2022", "localname": "JP", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "auth_ref": [] }, "iva_ExchangeRateOnInvoice": { "xbrltype": "pureItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExchangeRateOnInvoice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of exchange rate on ratio of invoice.", "label": "Exchange Rate On Invoice", "terseLabel": "Exchange rate on invoice" } } }, "auth_ref": [] }, "iva_ProceedsFromLicensingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ProceedsFromLicensingArrangements", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount paid on licensing arrangements.", "label": "Proceeds From Licensing Arrangements", "terseLabel": "Amount received on licensing arrangements" } } }, "auth_ref": [] }, "iva_MaximumDurationOfClinicalTrial": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "MaximumDurationOfClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum duration of the clinical trial of the entity.", "label": "Maximum Duration Of The Clinical Trial", "verboseLabel": "Maximum duration of Phase III trial" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r163", "r216" ] }, "iva_NumberOfCountriesInWhichClinicalTrialHasBeenApproved": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfCountriesInWhichClinicalTrialHasBeenApproved", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of countries in which the entity's clinical trial has been approved", "label": "Number Of Countries In Which The Clinical Trial Has Been Approved", "terseLabel": "Number of countries in which the Phase III trial has been approved" } } }, "auth_ref": [] }, "iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfWeeksUnderActiveTreatmentExtensionStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of weeks under the active treatment extension study of the entity.", "label": "Number Of Weeks Under The Active Treatment Extension Study", "verboseLabel": "Number of weeks under the active treatment extension study" } } }, "auth_ref": [] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and at hand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r235" ] }, "ifrs-full_LossesOnDisposalsOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LossesOnDisposalsOfNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Losses on disposals of non-current assets", "negatedLabel": "Disposals of assets" } }, "en": { "role": { "documentation": "The losses on disposals of non-current assets. [Refer: Non-current assets]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenue", "totalLabel": "Total revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r29", "r91", "r115", "r136", "r140", "r144", "r145", "r146", "r159", "r160", "r182" ] }, "iva_PercentageOfActivatedSitesCurrentlyOperatingUnderRevisedDesignOfClinicalTrial": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfActivatedSitesCurrentlyOperatingUnderRevisedDesignOfClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of activated sites currently operating under the revised design of the entity's clinical trial.", "label": "Percentage Of Activated Sites Currently Operating Under The Revised Design Of The Clinical Trial", "verboseLabel": "Percentage of activated sites currently operating under the revised design of Phase III trial" } } }, "auth_ref": [] }, "iva_DerivativeInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DerivativeInstrumentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for derivative instruments.", "label": "Derivative instruments" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium", "terseLabel": "Premiums related to share capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r165" ] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to change in fair value of derivatives instruments.", "label": "Increase Or Decrease In Borrowings Due To Change in Fair Value of Derivatives Instruments", "terseLabel": "Change in fair value of derivatives instruments" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain milestones, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement, Maximum Additional Amount Receivable Upon Achievement Of Certain Milestones", "terseLabel": "Maximum milestone payments receivable" } } }, "auth_ref": [] }, "country_KR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2022", "localname": "KR", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "KOREA, REPUBLIC OF", "terseLabel": "South Korea" } } }, "auth_ref": [] }, "iva_OtherComprehensiveIncomeNetOfTaxChangeInActuarialGainsAndLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherComprehensiveIncomeNetOfTaxChangeInActuarialGainsAndLosses", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to changes in actuarial gains and losses.", "label": "Other Comprehensive Income, Net Of Tax, Change In Actuarial Gains And Losses", "terseLabel": "Change in actuarial gains and losses" } } }, "auth_ref": [] }, "iva_NetChangeInOtherNonCurrentFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NetChangeInOtherNonCurrentFinancialAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount represents net change in other non-current financial assets.", "label": "Net change in other non-current financial assets", "terseLabel": "Net change in other non-current financial assets" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "totalLabel": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r213" ] }, "iva_AmountInvoicedToCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountInvoicedToCounterparty", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty.", "label": "Amount Invoiced To Counterparty", "terseLabel": "Milestone payment received", "verboseLabel": "Amount invoiced to counterparty" } } }, "auth_ref": [] }, "iva_August2023FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "August2023FinancingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for August 2023 financing.", "label": "August 2023 financing [Member]", "terseLabel": "August 2023 financing" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r10", "r46", "r162" ] }, "iva_ServiceContractWithAvantSanteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ServiceContractWithAvantSanteMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for service contract with Avant Sante.", "label": "Service contract with Avant Sante [Member]", "terseLabel": "Service contract with Avant Sante" } } }, "auth_ref": [] }, "iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Specific disclosure requirements for unaudited interim financial statements.", "label": "Description Of Accounting Policy For Specific Disclosure Requirements For Unaudited Interim Financial Statements [Policy Text Block]", "terseLabel": "Specific disclosure requirements for unaudited interim financial statements" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForAdditionalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountInvoicedToCounterpartyForAdditionalPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for additional payment.", "label": "Amount Invoiced To Counterparty For Additional Payment", "terseLabel": "Amount invoiced to counterparty for additional payment" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountInvoicedToCounterpartyForInitialPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for initial payment.", "label": "Amount Invoiced To Counterparty For Initial Payment", "terseLabel": "Amount invoiced to counterparty for milestone payment" } } }, "auth_ref": [] }, "iva_LongTermDepositForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermDepositForwardContractMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term deposit forward contract.", "label": "Long-Term Deposit Forward Contract [Member]", "terseLabel": "Long-term deposit forward contract" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "negatedLabel": "Share-based payments" } }, "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Percent of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r52", "r54", "r84" ] }, "iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicenseAndCollaborationAgreementUpfrontFeeReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Upfront Fee Receivable", "terseLabel": "Upfront payment receivable" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r19", "r87", "r182" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period", "terseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r215" ] }, "iva_LongTermAccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermAccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term accrued income.", "label": "Long-term accrued income" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Amortization", "verboseLabel": "Depreciation and impairment" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r39", "r42", "r61", "r66", "r69" ] }, "iva_ShortTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ShortTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for short-term deposit accounts.", "label": "Shortterm deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development costs" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r64" ] }, "ifrs-full_LongtermContractsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LongtermContractsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term contract liabilities" } }, "en": { "role": { "documentation": "This member stands for long-term contracts with customers." } } }, "auth_ref": [ "r186" ] }, "iva_LatePaymentOfInterestOnFrenchResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LatePaymentOfInterestOnFrenchResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of late payment of interest to be paid on French Research tax credit.", "label": "Late Payment of Interest on French Research Tax Credit", "negatedLabel": "Late payment interest on CIR 2013-2015" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange (gains) / losses" } }, "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r180", "r233" ] }, "ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost and losses (gains) arising from settlements, defined benefit plans", "negatedLabel": "Benefits for the period" } }, "en": { "role": { "documentation": "The amount of expense (income) resulting from past service cost and losses (gains) arising from settlements. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Past service cost, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements]" } } }, "auth_ref": [ "r222" ] }, "iva_EquityRecoveryLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "EquityRecoveryLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equity recovery loans.", "label": "Equity Recovery Loans [Member]", "terseLabel": "Equity recovery loans" } } }, "auth_ref": [] }, "iva_NumberOfLoanAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfLoanAgreements", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of loan agreements.", "label": "Number of Loan Agreements", "terseLabel": "Number of loan agreements" } } }, "auth_ref": [] }, "ifrs-full_LegalProceedingsProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LegalProceedingsProvisionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "AMR penalties" } }, "en": { "role": { "documentation": "This member stands for a provision for legal proceedings. [Refer: Other provisions [member]]" } } }, "auth_ref": [ "r171", "r173" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payment compensation expenses" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r3" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "iva_FinancingPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancingPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the financing period of loan.", "label": "Financing Period of Loan", "terseLabel": "Financing period of loan" } } }, "auth_ref": [] }, "iva_TransactionsCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TransactionsCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of transactions costs incurred during the period.", "label": "Transactions Costs", "negatedLabel": "Transaction costs" } } }, "auth_ref": [] }, "iva_WarrantAverageLife": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantAverageLife", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Average life used to calculate fair value of warrant.", "label": "Warrant Average Life", "verboseLabel": "Maturity (years)" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss", "negatedLabel": "Expense for the period" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]" } } }, "auth_ref": [ "r223" ] }, "iva_PercentageOfLoanGuaranteedByFrenchState": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfLoanGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of loan guaranteed by French state.", "label": "Percentage of Loan Guaranteed by French State", "terseLabel": "Percentage of loan guaranteed by French state" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "verboseLabel": "Property, Plant and Equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "label": "Due in 30 60 days" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } } }, "auth_ref": [ "r188", "r197", "r212", "r241" ] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to exchange rate change.", "label": "Increase or Decrease in Borrowings Due to Changes in Exchange Rates", "terseLabel": "Exchange rate change" } } }, "auth_ref": [] }, "ifrs-full_InterestCostsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InterestCostsCapitalised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Interest costs capitalised", "terseLabel": "Capitalized interest amount" } }, "en": { "role": { "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } } }, "auth_ref": [ "r212" ] }, "iva_NotionalAmountPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NotionalAmountPerTranche", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Notional amount per tranche", "label": "Notional amount per tranche" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinanceContractWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Finance contract with the European Investment Bank", "label": "Finance contract with European Investment Bank [Member]", "terseLabel": "Finance contract with EIB" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of property, plant and equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r41" ] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating expense", "totalLabel": "Total other operating expenses" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Subscription of borrowings", "verboseLabel": "Loan obtained" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r176" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } } }, "auth_ref": [ "r26" ] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks, under a stimulus economic plan.", "label": "Loan agreements with syndicate of French banks, under stimulus economic plan [Member]", "terseLabel": "Loan agreements with syndicate of French banks, under stimulus economic plan" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r117" ] }, "iva_CancellationTermForFundsNotDispersedAfterExecutionOfFinanceContract": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CancellationTermForFundsNotDispersedAfterExecutionOfFinanceContract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Cancellation term for funds not dispersed after execution of finance contract", "label": "Cancellation term for funds not dispersed after execution of finance contract" } } }, "auth_ref": [] }, "iva_Aga2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Aga2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2022 Plan).", "label": "AGA 2022 [Member]", "terseLabel": "AGA 2022" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r20", "r89", "r182" ] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)", "label": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l’Etat) [Member]", "terseLabel": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "terseLabel": "Other" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r4" ] }, "iva_NumberOfEntitiesBeingConsolidated": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfEntitiesBeingConsolidated", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of entities being consolidated", "label": "Number of entities being consolidated" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Schedule of maturity of long-term and short-term debt" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r125" ] }, "iva_DecreaseInBorrowingsThroughRepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreaseInBorrowingsThroughRepayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayments.", "label": "Decrease in borrowings through repayments", "negatedLabel": "Repayment of bank borrowings" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayment of lease liabilities.", "label": "Decrease in borrowings through repayment of lease liabilities", "negatedLabel": "Repayment of lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_LineItemsByFunctionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LineItemsByFunctionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Line items by function [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } } }, "auth_ref": [ "r209", "r212" ] }, "iva_IncreaseInBorrowingsThroughCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseInBorrowingsThroughCapitalizedInterest", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through capitalized interest.", "label": "Increase in borrowings through capitalized interest", "terseLabel": "Capitalized interests" } } }, "auth_ref": [] }, "iva_LongTermFinancialDebtDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermFinancialDebtDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Long-term financial debt, derivatives.", "label": "Derivatives", "terseLabel": "Long-term financial debt - derivatives" } } }, "auth_ref": [] }, "iva_CirAndOtherResearchTaxCreditsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CirAndOtherResearchTaxCreditsReceivable", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of CIR and other research tax credits receivable.", "label": "CIR and Other Research Tax Credits Receivable", "terseLabel": "CIR and other research tax credits receivable" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of ordinary shares", "verboseLabel": "Share capital" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r3" ] }, "iva_IncreaseInResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseInResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in research and development expense.", "label": "Increase in Research and Development Expense", "terseLabel": "Increase in research and development expense" } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Shareholders' equity", "verboseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r15", "r23", "r78", "r80", "r97", "r98", "r99" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Actuarial gains and losses on retirement benefit obligations (IAS 19)", "verboseLabel": "Actuarial gains and losses, net of deferred tax" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r21", "r32", "r222" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' equity" } } }, "auth_ref": [] }, "iva_BorrowingsMaximumExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BorrowingsMaximumExtensionTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Period up to which the maturity term of the borrowings can be extended.", "label": "Borrowings, Maximum Extension Term", "verboseLabel": "Extension of term of debt" } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "Operating expenses", "verboseLabel": "Notes to the income statement" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments", "terseLabel": "Decrease / (Increase) in short-term deposit accounts" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r231" ] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r56", "r57" ] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r237" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of financial position" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Noncurrent liabilities" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShorttermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term debt" } }, "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r179", "r181" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Net financial income" } }, "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r217" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease liabilities", "verboseLabel": "Lease" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r179", "r181" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Marketing - Business development expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r217" ] }, "iva_FairValueVariationGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FairValueVariationGains", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gains recognized for variation in fair value.", "label": "Fair Value Variation Gains", "terseLabel": "Fair value variation gains / losses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "verboseLabel": "Notes to the consolidated balance sheet" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetChangeInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedPeriodEndLabel": "At end of period", "negatedPeriodStartLabel": "At beginning of period", "totalLabel": "Total Obligation" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r43" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other miscellaneous payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_BorrowingCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BorrowingCostsIncurred", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Borrowing costs incurred", "terseLabel": "Borrowing costs" } }, "en": { "role": { "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current borrowings and current portion of non-current borrowings", "terseLabel": "Short-term debt" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r213" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Deferred and current taxes" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r75" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liabilities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r178" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average exchange rate for the period" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r134" ] }, "ifrs-full_BorrowingsByNameMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "BorrowingsByNameMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [member]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r237" ] }, "iva_ResearchAndDevelopmentMarketingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ResearchAndDevelopmentMarketingTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of Research and Development, Marketing.", "label": "Research and Development, Marketing [Table Text Block]", "terseLabel": "Schedule of research and development, marketing" } } }, "auth_ref": [] }, "iva_DisclosureOfNotesToConsolidatedBalanceSheetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfNotesToConsolidatedBalanceSheetTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for notes to the consolidated balance sheet.", "label": "Disclosure Of Notes To The Consolidated Balance Sheet [Text Block].", "terseLabel": "Notes to the consolidated balance sheet" } } }, "auth_ref": [] }, "iva_CurrentTaxCreditResearchIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditResearchIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from tax credit research.", "label": "Current Tax Credit Research Income", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementAmountInvoicedToCounterpartyNetOfWithholdingTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LicensingAndCollaborationAgreementAmountInvoicedToCounterpartyNetOfWithholdingTaxes", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received by the entity from licensing and collaborative agreement counterparty, net of withholding taxes.", "label": "Licensing And Collaboration Agreement, Amount Invoiced To Counterparty, Net Of Withholding Taxes", "terseLabel": "Net amount" } } }, "auth_ref": [] }, "iva_IfrsOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Ifrs Other Operating Income", "terseLabel": "Other" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInShortTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseInShortTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in short-term deposit accounts.", "label": "Increase (Decrease) In Short-Term Deposit Accounts", "negatedLabel": "Decrease in short-term deposit accounts" } } }, "auth_ref": [] }, "iva_SubsidiesIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubsidiesIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from subsidies.", "label": "Subsidies income", "terseLabel": "Subsidies" } } }, "auth_ref": [] }, "iva_AmountOfDepositsClosed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountOfDepositsClosed", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deposits of the entity closed during the period.", "label": "Amount Of Deposits Closed", "terseLabel": "Amount of deposits closed" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of shares outstanding used to calculate basic loss per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r58" ] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Total financial income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r217" ] }, "iva_NewShareWarrantPlansBsa2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewShareWarrantPlansBsa2019Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new share warrant plans (\"BSA 2019\").", "label": "BSA 2019" } } }, "auth_ref": [] }, "iva_AmountOfDepositsWhichHadChangeInMaturityTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmountOfDepositsWhichHadChangeInMaturityTerm", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deposits of the entity, which had change in maturity term.", "label": "Amount Of Deposits Which Had Change In Maturity Term", "terseLabel": "Amount of deposits with change in maturity term" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r127", "r128", "r147", "r152", "r153", "r154" ] }, "iva_TradeReceivablesRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradeReceivablesRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of trade receivables related to reinvoicing of share of costs incurred under the licensing and collaboration agreements.", "label": "Trade Receivables Relating To Reinvoicing Of Share Of Costs Under Licensing And Collaboration Agreement", "terseLabel": "Reinvoicing of share of costs incurred included in trade receivables" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r134" ] }, "iva_DavidNikodemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DavidNikodemMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company.", "label": "David Nikodem" } } }, "auth_ref": [] }, "iva_RevenueAndOperatingIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RevenueAndOperatingIncomeAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenue And Operating Income [Abstract]", "terseLabel": "Revenues and other income" } } }, "auth_ref": [] }, "iva_AdjustmentsForTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AdjustmentsForTaxCredits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Tax Credits", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_EntitysTotalForAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EntitysTotalForAssociatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for associates [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r53", "r55", "r96", "r155", "r157" ] }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" ], "lang": { "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Accounting Principles" } }, "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } } }, "auth_ref": [ "r156" ] }, "iva_IfrsScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "IFRS Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "iva_RevenueAndOtherIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RevenueAndOtherIncomeTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue and other income.", "label": "Revenue and Other Income [Table Text Block]", "terseLabel": "Schedule of revenue and other income" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r5" ] }, "iva_NotesToConsolidatedBalanceSheet": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NotesToConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the consolidated balance sheet" } } }, "auth_ref": [] }, "iva_ScheduleOfInventoryDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ScheduleOfInventoryDisclosureTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to inventories.", "label": "Schedule of Inventory Disclosure [Table]" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancialIncomeAndExpensesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of financial income and expense.", "label": "Financial Income and Expenses [Table Text Block]", "terseLabel": "Schedule of financial income and expenses" } } }, "auth_ref": [] }, "iva_DisclosureOfTradeReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfTradeReceivablesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of trade receivables.", "label": "Disclosure of Trade Receivables [Table Text Block]", "terseLabel": "Schedule of trade receivables" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "iva_OtherMiscellaneousPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherMiscellaneousPayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other miscellaneous payables.", "label": "Other miscellaneous payables" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Trade Receivables and Other Current Assets and Receivables [Line Items]", "terseLabel": "Trade receivables, tax receivables and other current assets" } } }, "auth_ref": [] }, "iva_OtherCurrentTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherCurrentTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of other tax receivables, classified as current.", "label": "Other Current Tax Receivables", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss." } } }, "auth_ref": [ "r209", "r212" ] }, "iva_OtherCurrentAssetsAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherCurrentAssetsAndReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other current assets and receivables as of balance sheet date.", "label": "Other Current Assets And Receivables", "totalLabel": "Other current assets and receivables" } } }, "auth_ref": [] }, "iva_DisclosureOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "iva_CurrentTaxCreditResearchCurrentYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTaxCreditResearchCurrentYear", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax credit research from current year, classified as current.", "label": "Current Tax Credit Research, Current Year", "terseLabel": "Receivable for current year", "verboseLabel": "Tax credits of current year" } } }, "auth_ref": [] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r53", "r55", "r96", "r155", "r157" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "iva_AgreementsConcerningProvisionOfFacilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AgreementsConcerningProvisionOfFacilities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails": { "parentTag": "iva_ContractualCapitalCommitmentReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of agreements concerning provision of facilities.", "label": "Agreements concerning the provision of facilities", "terseLabel": "Agreements concerning the provision of facilities" } } }, "auth_ref": [] }, "iva_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Company information" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r134" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "label": "Notional amount", "verboseLabel": "Total amount of loan" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r212" ] }, "iva_ContractManufacturingOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ContractManufacturingOrganizationsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Contract Manufacturing Organizations(CMO).", "label": "Contract Manufacturing Organizations [Member]", "terseLabel": "CMO" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share", "verboseLabel": "Nominal value" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r24" ] }, "iva_ContractualCapitalCommitmentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ContractualCapitalCommitmentReceived", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contractual capital commitment received.", "label": "Contractual Capital Commitment Received", "totalLabel": "Total commitments received" } } }, "auth_ref": [] }, "iva_CurrentTradeReceivablesAveragePaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CurrentTradeReceivablesAveragePaymentPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the average payment period for trade receivables.", "label": "Current Trade Receivables, Average Payment Period", "terseLabel": "Average payment period for trade receivables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r26" ] }, "iva_CompanyInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CompanyInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on company information.", "label": "Company Information [Text Block]", "terseLabel": "Company information" } } }, "auth_ref": [] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as operating activities", "verboseLabel": "Other" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r71" ] }, "iva_PharmaceuticalResearchAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PharmaceuticalResearchAssociatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pharmaceutical Research Associates.", "label": "Pharmaceutical Research Associates [Member]", "terseLabel": "Pharmaceutical Research Associates" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to trade receivables and other current assets and receivables.", "label": "Trade Receivables and Other Current Assets and Receivables [Table]" } } }, "auth_ref": [] }, "iva_CommitmentContractualPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentContractualPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitment contractual period.", "label": "Commitment Contractual Period", "terseLabel": "Commitment contractual period" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r209", "r212" ] }, "iva_ScheduleOfInventoryDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ScheduleOfInventoryDisclosureLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Schedule of Inventory Disclosure [Line Items]", "terseLabel": "Inventories" } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries", "negatedLabel": "Wages, salaries and similar costs" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r226" ] }, "iva_TermDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TermDepositMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for term deposit.", "label": "Term Deposit [Member]", "terseLabel": "Term deposit" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r41" ] }, "iva_AmendedPreviousCommitmentContractualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmendedPreviousCommitmentContractualAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amended previous commitment contractual.", "label": "Amended Previous Commitment Contractual Amount", "terseLabel": "Amended previous commitment contractual amount" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsSaleOfStockAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "IFRS Sale of Stock [Axis]" } } }, "auth_ref": [] }, "iva_CommitmentContractualBonusOrMalusCappedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CommitmentContractualBonusOrMalusCappedAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of commitment contractual bonus or malus capped amount.", "label": "Commitment Contractual Bonus Or Malus Capped Amount", "terseLabel": "Bonus or malus capped amount" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of estimates and judgment" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r208" ] }, "iva_AmendedPreviousCommitmentBonusOrMalusCappedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AmendedPreviousCommitmentBonusOrMalusCappedAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amended previous commitment bonus or malus capped.", "label": "Amended Previous Commitment Bonus Or Malus Capped Amount", "terseLabel": "Amended previous commitment bonus or malus capped amount" } } }, "auth_ref": [] }, "ifrs-full_LaterThanThreeMonthsAndNotLaterThanSixMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LaterThanThreeMonthsAndNotLaterThanSixMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Between 3 and 6 months" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three months and not later than six months." } } }, "auth_ref": [ "r190", "r192", "r198", "r201", "r204" ] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 6.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income (expenses)", "totalLabel": "Other operating income (expenses)" } }, "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r217" ] }, "iva_SubscriptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubscriptionPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription price per share in new issue of shares", "label": "Subscription Price Per Share", "terseLabel": "Subscription price" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsSaleOfStockDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of debt", "terseLabel": "Repayments of borrowings" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r177" ] }, "iva_StatementOfComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "StatementOfComplianceAbstract", "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Basis of preparation and statement of compliance" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r45", "r98" ] }, "ifrs-full_RepairsAndMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RepairsAndMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Repairs and maintenance expense", "negatedLabel": "Maintenance" } }, "en": { "role": { "documentation": "The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts." } } }, "auth_ref": [ "r217" ] }, "iva_ComponentsOfIncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ComponentsOfIncomeStatementAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the income statement" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r53", "r55", "r95" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalent", "periodEndLabel": "Net cash and cash equivalents at the end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r11", "r76", "r92" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r164" ] }, "iva_DisclosureOfComponentsOfIncomeStatementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfComponentsOfIncomeStatementTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatement" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for components of income statement.", "label": "Disclosure Of Components Of Income Statement [Text Block]", "terseLabel": "Notes to the income statement" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "StockIssuedDuringPeriodShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period.", "label": "Stock Issued During Period, Shares", "terseLabel": "Number of shares issued during the period" } } }, "auth_ref": [] }, "iva_AccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accounting Principles" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Short-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r101" ] }, "iva_DisclosureOfOtherFinancialInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfOtherFinancialInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other financial information.", "label": "Disclosure Of Other Financial Information [Text Block]", "terseLabel": "Other financial information" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "auth_ref": [] }, "iva_GoingConcernTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "GoingConcernTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to going concern.", "label": "Going Concern [Table]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r53", "r55", "r96" ] }, "iva_LongTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term deposit accounts.", "label": "Long-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based compensation expense" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r233" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r70", "r77" ] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "auth_ref": [] }, "iva_CollaborativeArrangementMilestonePaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CollaborativeArrangementMilestonePaymentsReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the cumulative amount of research funding received in a collaborative arrangement.", "label": "Collaborative Arrangement, Milestone Payments Received", "terseLabel": "Milestone payments received" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IncreaseDecreaseThroughShareWarrantsSubscriptionPremium", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase decrease in reserves resulting from BSA share warrants subscription premium.", "label": "Increase (Decrease) Through Share Warrants Subscription Premium", "terseLabel": "BSA share warrants subscription premium" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "RelatedPartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "label": "Related parties" } }, "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Joint ventures [member]; Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r50" ] }, "iva_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Vesting and holding period (year)" } } }, "auth_ref": [] }, "iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other non current assets.", "label": "Disclosure Of Other Noncurrent Assets [Table Text Block]", "terseLabel": "Schedule of other non current assets" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r41" ] }, "iva_GoingConcernLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "GoingConcernLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Going Concern [Line Items]", "terseLabel": "Going Concern" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "terseLabel": "Fair value variation through profit and loss" } }, "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r233" ] }, "iva_AccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued income.", "label": "Current accrued income" } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 }, "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net loss for the period", "totalLabel": "Net loss for the period", "verboseLabel": "Net income (loss) for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r2", "r27", "r72", "r79", "r81", "r139", "r141", "r182", "r199", "r200" ] }, "iva_NonCurrentSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NonCurrentSecurityDeposits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The non-current amount of security deposits.", "label": "Non-current Security Deposits", "terseLabel": "Security deposits" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term debt" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r179", "r181" ] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r59" ] }, "iva_IfrsotherFinancialInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsotherFinancialInformationLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "IFRSOther Financial Information [Line Items]", "terseLabel": "Events after the reporting date" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current liabilities [text block]", "terseLabel": "Schedule of other current liabilities" } }, "en": { "role": { "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]" } } }, "auth_ref": [ "r208" ] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r63" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetInventoriesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r40", "r62", "r65", "r67", "r68", "r114", "r120", "r121", "r202", "r205" ] }, "iva_IfrsotherFinancialInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsotherFinancialInformationTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other financial information.", "label": "IFRSOther Financial Information [Table]" } } }, "auth_ref": [] }, "iva_TermOfRoyaltyCertificate": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TermOfRoyaltyCertificate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of royalty certificate in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Term Of Royalty Certificate", "terseLabel": "Term of royalty certificate" } } }, "auth_ref": [] }, "iva_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other receivables.", "label": "Other receivables" } } }, "auth_ref": [] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r45", "r98" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Adjusted weighted average number of ordinary shares outstanding", "terseLabel": "Weighted average number of shares outstanding used to calculate diluted loss per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r58" ] }, "iva_PercentageOfDiscountToWeightedAverageTradingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfDiscountToWeightedAverageTradingPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to weighted average trading price of shares applied to the price of the stock offering.", "label": "Percentage Of Discount To Weighted Average Trading Price", "terseLabel": "Percentage of discount to weighted average trading price" } } }, "auth_ref": [] }, "iva_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradePayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for trade payables.", "label": "Trade payables" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherNonCurrentAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other non-current assets.", "label": "Other Non Current Assets [Table]" } } }, "auth_ref": [] }, "iva_PercentageOfAnuualRoyaltiesOnFutureNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PercentageOfAnuualRoyaltiesOnFutureNetSales", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of annual royalties over future net sales.", "label": "Percentage Of Anuual Royalties On Future Net Sales", "terseLabel": "Percentage of annual royalties on future net sales" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r59" ] }, "iva_IfrsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCashAndCashEquivalentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and cash equivalents" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherNonCurrentAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Non Current Assets [Line Items]", "verboseLabel": "Other Non Current Assets" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewShareWarrantPlansBsa2019BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 bis).", "label": "BSA 2019 bis" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019TerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewShareWarrantPlansBsa2019TerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 ter).", "label": "BSA 2019 ter" } } }, "auth_ref": [] }, "iva_ExpectedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ExpectedVolatility", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected volatility used to calculate fair value of warrants.", "label": "Expected volatility", "verboseLabel": "Volatility" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost", "terseLabel": "Amortized cost of loan" } }, "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r133", "r158" ] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r20", "r88", "r182" ] }, "iva_Bsa2017PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bsa2017PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2017 plan.", "label": "BSA - 2017 plan" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of going concern [text block]", "terseLabel": "Going concern" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r208" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r98" ] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r15" ] }, "iva_BsaPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BsaPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA plans.", "label": "BSA plans" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "iva_WarrantsFairValueAtGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsFairValueAtGrantDate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value at grant date per warrant.", "label": "Warrants, Fair Value at Grant Date", "verboseLabel": "Fair Value (k\u20ac)" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "verboseLabel": "Number of shares per BSA" } } }, "auth_ref": [] }, "iva_WarrantsSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "WarrantsSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityCharacteristicsOfBsaShareWarrantPlansDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The subscription price per warrant.", "label": "Warrants, Subscription Price", "verboseLabel": "Subscription price per share" } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other financial expenses" } }, "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } } }, "auth_ref": [ "r212" ] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Unaudited interim condensed consolidated statement of cash flows" } } }, "auth_ref": [] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment in progress" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r220" ] }, "iva_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "AtMarketOfferingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for at-the market offering (ATM).", "label": "At Market Offering [Member]", "terseLabel": "ATM" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Number of employees", "verboseLabel": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r212" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest cost" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r93", "r137", "r143" ] }, "iva_ClassOfWarrantOrRightGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ClassOfWarrantOrRightGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights granted.", "label": "Class of Warrant or Right, Granted", "verboseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r127", "r128", "r147", "r153" ] }, "iva_Bspce2013PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bspce2013PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE - 2013 plan.", "label": "BSPCE - 2013 Plan" } } }, "auth_ref": [] }, "iva_IfrsAdrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsAdrMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Ifrs ADR Member\n.", "label": "Adr [Member]", "terseLabel": "ADS" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.", "label": "Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory", "terseLabel": "Schedule of change in the provision recorded in respect of defined benefit schemes" } } }, "auth_ref": [] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, not classified as cash equivalents", "terseLabel": "Short-term deposits" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r213" ] }, "iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.", "label": "Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory", "terseLabel": "Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period" } } }, "auth_ref": [] }, "iva_FinancingFromSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "FinancingFromSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for financing from a syndicate of French banks.", "label": "Financing from a syndicate of French banks" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationLicensingAgreementWithHepalysDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r34" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets", "terseLabel": "Share based payment expense" } }, "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } } }, "auth_ref": [ "r113" ] }, "iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of expense recognized in the statement of income (loss)" } } }, "auth_ref": [] }, "iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other operating income (expense).", "label": "Disclosure Of Other Operating Income Expense [Table Text Block]", "terseLabel": "Schedule of other operating income and expenses" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInBorrowingsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfChangesInBorrowingsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of changes in borrowings.", "label": "Disclosure Of Changes In Borrowings [Table Text Block]", "verboseLabel": "Schedule of movements in the period break down" } } }, "auth_ref": [] }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of trade payables and other current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows used in financing activities" } } }, "auth_ref": [] }, "iva_TradePayablesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "TradePayablesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of trade payables and other current liabilities.", "label": "Trade Payables And Other Current Liabilities.", "totalLabel": "Trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_ShortTermDepositAccountsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "ShortTermDepositAccountsCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of short term deposits accounts, classified as current.", "label": "Short-Term Deposit Accounts, Current", "terseLabel": "Short-term deposit accounts" } } }, "auth_ref": [] }, "iva_LaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a time band of later than two months.", "label": "Due in more than 60 days" } } }, "auth_ref": [] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Total commitments given" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r212" ] }, "iva_RepaymentPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "RepaymentPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The period for repayment of loan.", "label": "Repayment Period of Loan", "terseLabel": "Repayment period for loan" } } }, "auth_ref": [] }, "iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription premium price per share of other equity instruments granted in share-based payment arrangement.", "label": "Subscription Premium Price Per Share Of Other Equity Instruments Granted", "terseLabel": "Subscription premium price per share (\u20ac)" } } }, "auth_ref": [] }, "iva_OtherAccruedTaxesAndEmployeeRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OtherAccruedTaxesAndEmployeeRelatedExpenses", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued taxes and employee related expenses.", "label": "Other Accrued taxes And Employee Related Expenses", "terseLabel": "Other accrued taxes and employeerelated expenses" } } }, "auth_ref": [] }, "iva_CashUnderLiquidityAgreementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "CashUnderLiquidityAgreementCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash under liquidity agreement, classified as current.", "label": "Cash Under Liquidity Agreement, Current", "terseLabel": "Liquidity agreement - Cash" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r207" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Net operating loss" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r169", "r217" ] }, "iva_NumberOfSharesPerOtherEquityInstrumentGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfSharesPerOtherEquityInstrumentGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.", "label": "Number Of Shares Per Other Equity Instrument Granted", "terseLabel": "Number of shares per AGA", "verboseLabel": "Number of shares entitled per warrant" } } }, "auth_ref": [] }, "iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Purchase Of Property Plant And Equipment And Intangile Assets Classified As Investing Activities", "label": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchases of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "iva_BspceAndBsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BspceAndBsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE and BSA share warrants.", "label": "BSPCE and BSA Share Warrants", "verboseLabel": "BSPCE share warrants and BSA share warrants" } } }, "auth_ref": [] }, "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "OperatingExpenseExcludingOtherOperatingIncomeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amount of all operating expenses.", "label": "Operating Expense Excluding Other Operating Income Expense", "negatedTotalLabel": "Total operating expenses" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Translation reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r48", "r161" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LegalEntityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationAmendmentsToContractCroWithPharmaceuticalResearchAssociatesBvServiceAgreementWithSummitClinicalResearchLlcDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative Line items", "verboseLabel": "Collaborative Arrangements" } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r134" ] }, "iva_NumberOfLoansObtainedGuaranteedByFrenchState": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NumberOfLoansObtainedGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of loans obtained which are guaranteed by the french state.", "label": "Number Of Loans Obtained Guaranteed By The French State", "verboseLabel": "Number of loans obtained guaranteed by the french state" } } }, "auth_ref": [] }, "iva_LongTermSecurityDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "LongTermSecurityDepositsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term security deposits.", "label": "Long-term security deposits" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Schedule of exchange rates" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r49" ] }, "ifrs-full_UnderlyingEquityInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "UnderlyingEquityInstrumentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument [member]" } }, "en": { "role": { "documentation": "This member represents the standard value for the \u2018Underlying equity instrument and depositary receipts\u2019 axis if no other member is used." } } }, "auth_ref": [ "r212" ] }, "iva_BonusShareAwardPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BonusShareAwardPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFreeShareAwardsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share award plans.", "label": "Bonus Share Award Plans [Member]" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r216" ] }, "iva_InventivaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "InventivaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradeReceivablesAndOtherCurrentAssetsAndReceivablesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementNarrativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToIncomeStatementPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva Inc, U.S. affiliate.", "label": "Inventiva Inc [Member]", "terseLabel": "Inventiva Inc." } } }, "auth_ref": [] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetOtherNonCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r127", "r128", "r147", "r152", "r153", "r154" ] }, "iva_BsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrants.", "label": "BSA share warrants" } } }, "auth_ref": [] }, "iva_Bspce2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "Bspce2021PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2021 plan.", "label": "BSPCE 2021" } } }, "auth_ref": [] }, "ifrs-full_NotLaterThanOneMonthMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "localname": "NotLaterThanOneMonthMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetTradePayablesDetails" ], "lang": { "en-us": { "role": { "label": "Due in 30 days" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one month." } } }, "auth_ref": [ "r189", "r191", "r198" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r207" ] }, "iva_BspcePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "BspcePlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE plans.", "label": "BSPCE plans" } } }, "auth_ref": [] }, "iva_NewBsa2021ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "NewBsa2021ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021 share warrant plan.", "label": "BSA 2021" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20230630", "localname": "IfrsClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToConsolidatedBalanceSheetShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Outstanding", "terseLabel": "Number of share warrants outstanding", "verboseLabel": "Number of BSA outstanding" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard", "URIDate": "2022-03-24" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2022-03-24" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2022-03-24" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2022-03-24" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2022-03-24" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2022-03-24" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard", "URIDate": "2022-03-24" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2022-03-24" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard", "URIDate": "2022-03-24" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2022-03-24" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2022-03-24" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2022-03-24" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2022-03-24", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2022-03-24" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard", "URIDate": "2022-03-24" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2022-03-24" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2022-03-24" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2022-03-24" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard", "URIDate": "2022-03-24" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2022-03-24" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2022-03-24", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2022-03-24", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2022-03-24" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2022-03-24", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS21_g51-57__IAS21_g51-57_TI", "URIDate": "2022-03-24" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2022-03-24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2022-03-24", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2022-03-24", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2022-03-24", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2022-03-24", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2022-03-24", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2022-03-24", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard", "URIDate": "2022-03-24" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86&doctype=Standard", "URIDate": "2022-03-24" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard", "URIDate": "2022-03-24" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2022-03-24" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2022-03-24", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard", "URIDate": "2022-03-24" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2022-03-24", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22&doctype=Standard", "URIDate": "2022-03-24" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2022-03-24" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2022-03-24" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "2", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2022-03-24", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard", "URIDate": "2022-03-24" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2022-03-24" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard", "URIDate": "2022-03-24" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2022-03-24" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard", "URIDate": "2022-03-24" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2022-03-24" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2022-03-24" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2022-03-24", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2022-03-24", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2022-03-24" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2022-03-24" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2022-03-24" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2022-03-24" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2022-03-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2022-03-24" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard", "URIDate": "2022-03-24" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2022-03-24" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2022-03-24" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2022-03-24" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2022-03-24" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8&doctype=Standard", "URIDate": "2022-03-24" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2022-03-24" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2022-03-24" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2022-03-24" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2022-03-24" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2022-03-24", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2022-03-24", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2022-03-24" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard", "URIDate": "2022-03-24" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2022-03-24" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2022-03-24" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2022-03-24" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2022-03-24", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2022-03-24" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective on first application of IFRS 9", "Name": "IFRS", "Number": "4", "IssueDate": "2022-03-24", "Paragraph": "39L", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2022-03-24" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective on first application of IFRS 9", "Name": "IFRS", "Number": "4", "IssueDate": "2022-03-24", "Paragraph": "39M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard", "URIDate": "2022-03-24" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2023-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "4", "IssueDate": "2022-03-24", "Paragraph": "39J", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24" }, "r160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24" }, "r161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24" }, "r162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard", "URIDate": "2022-03-24" }, "r163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard", "URIDate": "2022-03-24" }, "r164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24" }, "r165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24" }, "r166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2022-03-24" }, "r167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2022-03-24" }, "r169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2022-03-24", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2022-03-24", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24" }, "r171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "87", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_87&doctype=Standard", "URIDate": "2022-03-24" }, "r172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_88&doctype=Standard", "URIDate": "2022-03-24" }, "r173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Section": "Example 10 A court case", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10__IAS37_IE_C_ex10_TI", "URIDate": "2022-03-24" }, "r174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2022-03-24" }, "r175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24" }, "r176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2022-03-24" }, "r177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2022-03-24" }, "r178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24" }, "r179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2022-03-24" }, "r180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2022-03-24" }, "r181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2022-03-24" }, "r182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2022-03-24", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24" }, "r185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2022-03-24", "Paragraph": "B89", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24" }, "r188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24" }, "r189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2022-03-24" }, "r197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG20D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2022-03-24" }, "r199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2023-01-01", "Name": "IFRS", "Number": "17", "IssueDate": "2022-03-24", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24" }, "r200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective on first application of IFRS 9", "Name": "IFRS", "Number": "4", "IssueDate": "2022-03-24", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24" }, "r201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG29", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG29", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" }, "r207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24" }, "r209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24" }, "r210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24" }, "r211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24" }, "r212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24" }, "r213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24" }, "r214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24" }, "r215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24" }, "r216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard", "URIDate": "2022-03-24" }, "r217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24" }, "r218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80&doctype=Standard", "URIDate": "2022-03-24" }, "r219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2022-03-24", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24" }, "r220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24" }, "r221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2022-03-24", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24" }, "r222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2022-03-24" }, "r223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141&doctype=Standard", "URIDate": "2022-03-24" }, "r224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_5&doctype=Standard", "URIDate": "2022-03-24" }, "r225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2022-03-24" }, "r226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2022-03-24", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard", "URIDate": "2022-03-24" }, "r227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "37", "IssueDate": "2022-03-24", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard", "URIDate": "2022-03-24" }, "r228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2022-03-24", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24" }, "r229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2022-03-24", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24" }, "r230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2022-03-24", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24" }, "r231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard", "URIDate": "2022-03-24" }, "r232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2022-03-24" }, "r233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24" }, "r234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24" }, "r235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2022-03-24", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24" }, "r237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24" }, "r238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Effective 2023-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24" }, "r239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2023-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2022-03-24", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24" }, "r240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37&doctype=Standard&book=b", "URIDate": "2022-03-24" }, "r242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2022-03-24", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24" } } }